Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor Drugs Using i-DPS Technology

 Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor Drugs Using i-DPS Technology

Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor Drugs Using i-DPS Technology

Shots:

  • Collaboration is for development of novel drugs utilizing B. longum as a drug delivery carrier for in-situ Delivery and Production System (i-DPS) Technology. Astellas has option rights to further develop and commercialize the develop product
  • Anaeropharma has developed APS001F, a recombinant Bifidobacterium expresses Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is currently evaluated under P-I trial in the US
  • Bifidobacterium is an anaerobic, nonpathogenic bacterium existing as enteroflora in the human body. i-DPS technology is designed to deliver B. longum which expresses active molecules specifically at hypoxic disease sites

Click here to read full press release/ article | Ref: Anaeropharma | Image: Statnews

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post